Education
About Us
Working with TipRanks
Follow Us
ATAI Life Sciences (ATAI)
NASDAQ:ATAI
ATAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $2.57
Previous CloseN/A
Volume1.44M
Average Volume (3M)1.87M
Market Cap
$255.82M
Enterprise Value$109.80M
Total Cash (Recent Filing)-$30.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 20, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding198,306,460
10 Day Avg. Volume1,975,103
30 Day Avg. Volume1,867,494
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)933.59
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$8.00Price Target Upside520.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityAtai's well-capitalized balance sheet, execution across multiple programs, and upcoming data readouts are expected to further de-risk the pipeline.
Pipeline ProgressPhase 2b results for RL-007 in cognitive impairment associated with schizophrenia could position atai as a leader in pro-cognitive therapeutics.
Bears Say
Dependency On Trial OutcomesTopline data from the Phase 2b BPL-003 study for treatment-resistant depression is expected to be of particular focus to investors.
Market PerceptionRL-007's potential is considered underappreciated, and positive mid-2025 data in cognitive impairment associated with schizophrenia could be a significant driver of upside.
---
Ownership Overview
33.43% Insiders
0.53% Mutual Funds
2.21% Other Institutional Investors
63.23% Public Companies and
Individual Investors
ATAI FAQ
What was ATAI Life Sciences’s price range in the past 12 months?
ATAI Life Sciences lowest stock price was $1.03 and its highest was $2.56 in the past 12 months.
What is ATAI Life Sciences’s market cap?
ATAI Life Sciences’s market cap is $255.82M.
When is ATAI Life Sciences’s upcoming earnings report date?
ATAI Life Sciences’s upcoming earnings report date is May 20, 2025 which is in 35 days.
How were ATAI Life Sciences’s earnings last quarter?
ATAI Life Sciences released its earnings results on Mar 27, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.159 by -$0.081.
Is ATAI Life Sciences overvalued?
According to Wall Street analysts ATAI Life Sciences’s price is currently Undervalued.
Does ATAI Life Sciences pay dividends?
ATAI Life Sciences does not currently pay dividends.
What is ATAI Life Sciences’s EPS estimate?
ATAI Life Sciences’s EPS estimate is -0.17.
How many shares outstanding does ATAI Life Sciences have?
ATAI Life Sciences has 198,306,460 shares outstanding.
What happened to ATAI Life Sciences’s price movement after its last earnings report?
ATAI Life Sciences reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.159. Following the earnings report the stock price went up 6.803%.
Which hedge fund is a major shareholder of ATAI Life Sciences?
Currently, no hedge funds are holding shares in ATAI
---
ATAI Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (520.16% Upside)
$8.00 (520.16% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 27.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.00%
12-Months-Change
Fundamentals
Return on Equity
-62.43%
Trailing 12-Months
Asset Growth
-35.92%
Trailing 12-Months
Company Description
ATAI Life Sciences
ATAI Life Sciences (ATAI) is a biotechnology company focused on the development of psychedelic and non-psychedelic compounds for the treatment of mental health disorders. Founded in 2018, the company aims to transform the treatment of mental health by leveraging innovative science, technology, and academic partnerships. ATAI operates a decentralized platform model, investing in and incubating various subsidiary companies that focus on different aspects of mental health treatment, including drug development and digital therapeutics.
---
ATAI Stock 12 Month Forecast
Average Price Target
$8.00
▲(520.16% Upside)
Technical Analysis
Taysha Gene Therapies
―
Olema Pharmaceuticals
―
Monte Rosa Therapeutics
―
2seventy bio
―
Septerna, Inc.
―
Best Analysts Covering ATAI
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-15.69%
reiterated a buy rating 30 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -15.69% per trade.
---